Роль трабектедина в лечении сарком мягких тканей: обзор современных данных
https://doi.org/10.17650/2782-3687-2021-13-3-16-27
Аннотация
Саркомы мягких тканей – редкая гетерогенная группа злокачественных опухолей мезенхимального происхождения, которые составляют менее 1 % всех онкологических заболеваний. Актуальная проблема лекарственной терапии данной патологии, особенно при распространенном процессе, – низкая эффективность применяемых схем лечения. Трабектедин является одним из активных противоопухолевых агентов, одобренных для лечения сарком мягких тканей в случае неэффективности стандартной химиотерапии.
В данной статье представлен обзор публикаций по теме эффективности трабектедина и его роли в лечении пациентов с саркомами мягких тканей.
Об авторах
А. А. Феденко
ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России
Россия
Россия
Россия, 125284 Москва, 2-й Боткинский проезд, 3
А. А. Тарарыкова
ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава России
Россия
Россия
Анастасия Алексеевна Тарарыкова
Россия, 115478 Москва, Каширское шоссе, 24
Список литературы
1. Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадова. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020. 252 с.
2. Amercan Cancer Society. Cancer Facts & Figures 2017. Atlanta Am Cancer Soc 2017. Avaliable at: https://www.cancer.org/research/cancer-facts-statistics/all-cancerfacts-figures/cancer-facts-figures-2017.html.
3. Le Cesne A., Blay J.-Y., Cupissol D. et al. A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial. Ann Oncol 2021;32(8):1034–44. DOI: 10.1016/j.annonc.2021.04.014.
4. Delaloge S., Yovine A., Taamma A. et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients – preliminary evidence of activity. J Clin Oncol 2001;19(5):1248–55. DOI: 10.1200/JCO.2001.19.5.1248.
5. Yovine A., Riofrio M., Blay J.Y. et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004;22(5):890–9. DOI: 10.1200/JCO.2004.05.210.
6. Garcia-Carbonero R., Supko J.G., Manola J. et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004;22(8):1480–90. DOI: 10.1200/JCO.2004.02.098.
7. Blay J.Y., Italiano A., Ray-Coquard I. et al. Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program. BMC Cancer 2013;13:1–8. DOI: 10.1186/1471-2407-13-64.
8. Herrero A.B., Martín-Castellanos C., Marco E. et al. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res 2006;66(16):8155–62. DOI: 10.1158/0008-5472.CAN-06-0179.
9. Grosso F., Jones R.L., Demetri G.D. et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007;8(7):595–602. DOI: 10.1016/S1470-2045(07)70175-4.
10. Demetri G.D., Chawla S.P., Mehren M. von et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009;27(25):4188–96. DOI: 10.1200/JCO.2008.21.0088.
11. Demetri G.D., Chawla S.P., Mehren M. von et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol 2015;34(8):786–93. DOI: 10.1200/JCO.2015.62.4734.
12. Patel S., Mehren M., Reedet D.R. at al. Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Cancer 2019;125(15):2610–20. DOI: 10.1002/cncr.32117.
13. De Sande González L.M., Martin-Broto J., Kasper B. et al. Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma. Expert Rev Anticancer Ther 2020;20(11):957–63. DOI: 10.1080/14737140.2020.1822744.
14. Samuels B.L., Chawla S., Patel S. et al. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study. Ann Oncol 2013;24(6):1703–9. DOI: 10.1093/annonc/mds659.
15. Ploner F., Lamm W., Schur S. et al. The Austrian experience with trabectedin in non-selected patients with metastatic soft tissue sarcoma (STS). J Cancer Res Clin Oncol 2013;139(8):1337–42. DOI: 10.1007/s00432-013-1447-8.
16. Gounaris I., Hatcher H.M., Davidson D. et al.Trabectedin for advanced soft tissue sarcomas: A single institution experience. Futur Oncol 2014;10(11):1843–51. DOI: 10.2217/FON.14.10.
17. Le Cesne A., Ray-Coquard I., Duffaud F. et al. Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group. Eur J Cancer 2015;51(6):742–50. DOI: 10.1016/j.ejca.2015.01.006.
18. De Sanctis R., Marrari A., Marchetti S. et al. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipoand leiomyosarcoma. Drug Des Devel Ther 2015;9:5785–91. DOI: 10.2147/DDDT.S92395.
19. Buonadonna A., Benson C., Casanova J. et al. A noninterventional, multicenter, prospective phase IV study of trabectedin in patients with advanced soft tissue sarcoma. Anticancer Drugs 2017;28(10):1157–65. DOI: 10.1097/CAD.0000000000000560.
20. Shamai S., Merimsky O. Trabectedin for advanced soft tissue sarcoma: ten year real-life perspective. Isr Med Assoc J 2018;20(10):599–603. DOI: 10.1200/JCO.2017.35.15_suppl.11060.
21. Kotecki N., Cesne A.L., Tresch-Bruneel E. et al. Update of the T-DIS randomized phase II trial: trabectedin rechallenge versus continuation in patients (pts) with advanced soft tissue sarcoma (ASTS). Ann Oncol 2016;27(Suppl 6):vi486. DOI: 10.1093/annonc/mdw388.12.
22. Paz-Ares L., López-Pousa A., Poveda A. et al. Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating cotreatment with dexamethasone. Invest New Drugs 2012;30(2)729–40. DOI: 10.1007/s10637-010-9561-9.
23. Jordan K., Jahn F., Jordan B. et al. Trabectedin: Supportive care strategies and safety profile. Crit Rev Oncol Hematol 2015;94(3):279–90. DOI: 10.1016/j.critrevonc.2015.02.012.
24. Shewach D.S., Lawrence T.S. Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage. J Clin Oncol 2008;27(33):198–200. DOI: 10.1200/JCO.2008.21.6473.
25. Reuben D.Y. A prolonged response and characteristics of trabectedin treatment of metastatic soft tissue sarcoma. J Med Cases 2021;12(4):160–3. DOI: 10.14740/jmc3655.
26. Cordeiro M., Casan J.M., Rodrigues J. et al. Long-term response after 94 cycles of trabectedin in a patient with metastatic leiomyosarcoma of the lower extremity. Case Rep Oncol 2020;13(1):113–9. DOI: 10.1159/000505393.
27. Cesne A.L., Judson I., Maki R. et al. Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials. Br J Cancer 2013;109(7):1717–24. DOI: 10.1038/bjc.2013.524.
28. Blay J.Y., Blay J.Y., Judson I. et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group trial. J Clin Oncol 2005;23(3):576–84. DOI: 10.1200/JCO.2005.01.180.
29. Garcia-Carbonero R., Supko J.G., Maki R.G. et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 2005;23(24):5484–92. DOI: 10.1200/JCO.2005.05.028.
30. Kawai A., Hartzell T.L., Sinha I. el al. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocationrelated sarcoma: a randomised, open-label, phase 2 study. Lancet Oncol 2015;16(4):406–16. DOI: 10.1016/S1470-2045(15)70098-7.
31. Grosso F., D’Ambrosio L., Zucchetti M. et al. Pharmacokinetics, safety, and activity of trabectedin as first-line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: a phase 2 study (TR1US study) from the Italian Sarcoma Group. Cancer 2020;126(21):4726–34. DOI: 10.1002/cncr.33120.
32. Pautier P., Floquet A., Chevreau C. et al. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. Lancet Oncol 2015;16(4):457–64. DOI: 10.1016/S1470-2045(15)70070-7.
33. Martin-Broto J., Pousa A.L., Peñas Las de R. et al. Randomized phase II study of trabectedin and doxorubicin compared with doxorubicin alone as first-line treatment in patients with advanced soft tissue sarcomas: a Spanish group for research on sarcoma study. J Clin Oncol 2016;34(19):2294–302. DOI: 10.1200/JCO.2015.65.3329.
34. Pautier P., Floquet A., Chevreau C. et al. A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery. ESMO Open;2021;6(4):100209. DOI: 10.1016/j.esmoop.2021.100209.
35. Pautier P., Italiano A., Piperno-Neumann S. et al. LMS-04 study: a randomised, multicenter, phase III study comparing doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin in non-progressive patients as first-line therapy, in patients with metastatic or unresectable leiomyosarc. Ann Oncol 2021;32(5):S1283–346. DOI: 10.1016/annonc/annonc741.
36. Grosso F., Sanfilippo R., Virdis E. et al. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol 2009;20(8):1439–44. DOI: 10.1093/annonc/mdp004.
37. Takahashi M., Takahashi S., Araki N. et al. Efficacy of trabectedin in patients with advanced translocation related sarcomas: pooled analysis of two phase II studies. Oncologist 2017;22(8):979–88. DOI: 10.1634/theoncologist.2016-0064.
38. Martínez-Trufero J., Sande-González de L.M., Luna P. et al. A growth modulation indexbased GEISTRA SCORE as a new prognostic tool for trabectedin efficacy in patients with advanced soft tissue sarcomas: a Spanish group for sarcoma research (GEIS) retrospective study. Cancers (Basel) 2021;13(4):1–15. DOI: 10.3390/cancers13040792.
39. Von Hoff D.D. There are no bad anticancer agents, only bad clinical trial designs-twentyfirst Richard and Hinda Rosenthal Foundation Award Lecture. Clin Cancer Res 1998; 4(5):1079–86.
40. Gronchi A., Hindi N., Cruz J. et al. Trabec-tedin and radiotherapy in soft tissue sarcoma (trasts): results of a phase i study in myxoid liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups. Clinical Medicine 2019;9:35–43. DOI: 10.1016/j.eclinm.2019.03.007.
41. Hindi N., García I.C., Sánchez-Camacho A. et al. Trabectedin plus radiotherapy for advanced soft-tissue sarcoma: experience in forty patients treated at a sarcoma reference center. Cancers (Basel) 2020;12(12):3740. DOI: 10.3390/cancers12123740.
Рецензия
Для цитирования:
Феденко А.А., Тарарыкова А.А. Роль трабектедина в лечении сарком мягких тканей: обзор современных данных. Саркомы костей, мягких тканей и опухоли кожи. 2021;13(3):16-26. https://doi.org/10.17650/2782-3687-2021-13-3-16-27
For citation:
Fedenko A.A., Tararykova A.A. Trabectedin in the treatment of soft tissue sarcomas: up to date data. Bone and soft tissue sarcomas, tumors of the skin. 2021;13(3):16-26. (In Russ.) https://doi.org/10.17650/2782-3687-2021-13-3-16-27
Просмотров:
405
Послать статью по эл. почте 
